A Randomized Phase II Trial of Temozolomide (TMZ) with/without Recentin (AZD2171) in Patients with unresectable Stage IV Malignant Melanoma.
Study identifier:IRUS21710038
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Other
Official Title
A Randomized Phase II Trial of Temozolomide (TMZ) with/without Recentin (AZD2171) in Patients with unresectable Stage IV Malignant Melanoma.
Medical condition
Colorectal Cancer
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
-
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
